retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide, a (GLP1, GIP, glucagon), just released 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Dr. - First-in-Class 'Triple-G'! Retatrutide,
Description
Sato T, Shimizu T, Fujita H, Imai Y, Drucker DJ, Seino Y, et al
EBioMedicine 93 , 104642 (2023)

Furthermore, the odds ratio increases as the cumulative dose increases

Despite the range of brand names, the market is dominated by just two companies: Eli Lilly in the U.S

PMID: 8462365
